Diligence memo · auto-generated · as of July 2, 2026
NextEvo, Inc.
NextEvo, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
NextEvo, Inc. operates in Pharmaceuticals, based in CONSHOHOCKEN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NextEvo, Inc. has raised $600K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $600K on 2025-01-13.
Most recent recorded round closed around 2025-01-13.
Valuation (modeled)modeled
Provath models NextEvo, Inc. at approximately $2.0M (range $336K–$5.7M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.36× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era. Within the normal band (136% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 18 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 14% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 4% of those peers.
Closest niche peers: Fedora Pharmaceuticals Inc., PRG FlowChem, Inc., Adora Animal Health Corp, ABLi Therapeutics, Inc., Etheros Pharmaceuticals Corp..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.